Lemaitre Vascular ( (LMAT) ) has released its Q4 earnings. Here is a breakdown of the information Lemaitre Vascular presented to its investors.
LeMaitre Vascular, Inc., a company specializing in vascular devices, implants, and services, operates within the medical device industry, focusing on the treatment of peripheral vascular disease. The company is known for its innovative solutions catering to vascular surgeons worldwide.
In its latest financial report for the fourth quarter of 2024, LeMaitre Vascular announced a robust performance with a 14% increase in sales compared to the same period in 2023. The company also declared a 25% increase in its quarterly dividend, reflecting its strong financial health and commitment to returning value to shareholders.
Key financial highlights include a sales figure of $55.7 million, a gross margin improvement to 69.3%, and an operating income of $12.9 million, marking a 26% increase. Earnings per diluted share rose by 30% to $0.49. The company saw significant sales growth in its grafts, carotid shunts, and catheters product lines, with notable regional sales increases in APAC, EMEA, and the Americas. Additionally, the approval of XenoSure patches in China is expected to bolster future sales.
Looking ahead, LeMaitre Vascular projects continued growth with sales guidance for Q1 2025 set between $56.7 million and $58.7 million, and full-year 2025 sales expected to reach between $235.4 million and $242.8 million. The company remains optimistic about maintaining its operational efficiency and expanding its market presence.
With a strong cash position of $299.7 million, LeMaitre is well-positioned to explore strategic opportunities and further enhance shareholder value through initiatives like the recently authorized $75 million share repurchase program.